13 citations
,
March 2020 in “Frontiers in cell and developmental biology” A substance called TCQA could potentially darken hair by activating certain genes and increasing melanin.
2 citations
,
February 2025 in “Archives of Dermatological Research” Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.
40 citations
,
July 2023 in “Clinical Pharmacology & Therapeutics” Targeted protein degraders show promise in treating cancer but need to target more diverse proteins.
July 2025 in “Pakistan Journal of Intensive Care Medicine” Clobetasol propionate 0.05% ointment is more effective than tacrolimus 0.1% ointment for treating alopecia areata.
November 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” TYK2 inhibition may help treat alopecia areata by promoting hair growth and reducing immune response.
10 citations
,
May 2019 in “BMC Complementary and Alternative Medicine” The extract from Bacillus/Trapa japonica fruit helps increase hair growth and could be a potential treatment for hair loss.
4 citations
,
January 2009 in “International journal of trichology” Minoxidil topical foam is a better, less irritating treatment for hair loss.
July 2025 in “International Journal of Health and Medicine” Tamsulosin and solifenacin together effectively reduce symptoms in BPH patients.
August 2020 in “Benha Journal of Applied Sciences” Higher FABP4 levels may help diagnose androgenetic alopecia early.
May 2022 in “Journal of Immunology” A parasite molecule can speed up skin healing and reduce scarring.
4 citations
,
July 2023 in “Nature Medicine” The FDA approved a new Pfizer drug for hair loss in teens.
2 citations
,
May 2024 in “The Turkish Journal of Gastroenterology” Tacrolimus treatment for autoimmune hepatitis can cause hair loss.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly”
September 2022 in “bioRxiv (Cold Spring Harbor Laboratory)” A parasite-derived molecule speeds up skin healing and affects immune cell behavior without increasing scarring.
7 citations
,
December 2021 in “European Respiratory Review” The document concludes that diagnosing and treating Interstitial Pneumonia with Autoimmune Features (IPAF) is challenging, needs a multidisciplinary approach, and further research for better diagnostic criteria and treatments. It also emphasizes regular checks for Connective Tissue Disease symptoms in all patients with Interstitial Lung Disease.
1 citations
,
November 2018 in “immuneACCESS” Expanded CD8+ T cells are linked to Alopecia Areata and may cause relapse after treatment.
April 2018 in “Journal of Investigative Dermatology” BLZ-100 is safe for use in skin cancer surgery and may help identify cancerous tissue.
January 2026 in “International Journal of Medical and All Body Health Research” PRP is safer and has a lower relapse rate than TAC for treating alopecia areata.
April 2016 in “Journal of The American Academy of Dermatology” The study found that Temporal Triangular Alopecia often starts in early childhood, mainly affects the left side of the scalp, and has no effective treatment except surgery.
9 citations
,
October 2025 in “MedComm” PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
18 citations
,
September 1972 in “British Journal of Pharmacology” PCPA induces hypersexual behavior in male rats regardless of age or castration status.
14 citations
,
July 2021 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” Interleukin levels are higher in alopecia areata patients but don't predict disease severity or duration.
March 2012 in “Society for Endocrinology BES 2012” A new method was developed to analyze certain hormones and drugs in human blood efficiently.
April 2019 in “Journal of Investigative Dermatology” Frontal Fibrosing Alopecia involves disrupted cholesterol pathways, fibrosis, and increased mast cells.
May 2022 in “Reactions Weekly”
CD4 T cells need IFN-γ to cause hair loss in alopecia areata.
January 2019 in “Oncogen” Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.
July 2026 in “Preprints.org” Tirzepatide users experience more hair loss than semaglutide users.
Teprotumumab for thyroid eye disease commonly causes fatigue, brittle nails, dry eyes, hair loss, muscle spasms, and dry mouth, with rare serious events like blood clots.